medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2011, Number 3

Next >>

Rev Mex Patol Clin Med Lab 2011; 58 (3)

Bone turnover markers and osteoporosis

Barba EJR

Language: Spanish
References: 109
Page: 113-137
PDF size: 471.16 Kb.


ABSTRACT

Thanks to the advances in the field of the investigation, it at the present time is possible prevent the development of illnesses that they could be detected during the childhood or even before the birth, what allows to take actions guided to improve the quality of life in the mature age of those individual payees of happiness affections. However, in spite of these advances, the osteoporosis has won land how one of the problems of health that affect to millions of people in everybody, and if joined to this, we considered that the expectations of life on the average in the population is near to the 75 years, that this illness affects mainly to postmenopausic women, and that the overlife of the woman is old that in the males, the presage is contradictory for this group of people. Fortunately, we today could say that we had the diagnostic tools appropriate in order to detect this illness or those patients that they have the risk of developing it, the problem resides then, in the lack of consents that permit their standardization in order to could be used like methods of screening.


REFERENCES

  1. Stevens A, Lowe J. Histologia Humana. 2a ed. Madrid: Harcourt Brace; 1999. p. 234–247.

  2. Lafita J. Fisiología y fisiopatología ósea. An Sist Sanit Navar 2003; 26 (suppl 3): 7–17.

  3. Barletta VJ. Correlación de la determinación de desoxipiridinolina con los valores de densitometría ósea en mujeres postmenopáusicas. Tesis digitales UNMSM.

  4. Fernández-Tresguerres-Hernández-Gil I et al. Physiological bases of bone regeneration. Parte I: Histology and physiology of bone tissue. Med Oral Patol Oral Cir Bucal 2006: E47-E51.

  5. Fernández-Tresguerres-Hernández-Gil I et al. Bases fisiológicas de la regeneración osea. Parte II: El proceso de remodelado. Med Oral Patol Oral Cir Bucal 2006; 11: E151-E157.

  6. Reynaga MB. Marcadores bioquímicos del remodelamiento óseo. Utilidad clínica. Act Bioquim Clin Latinoam 2009; 43 (2): 177-193.

  7. Mandalunis MP. Remodelación ósea. Actualización osteología 2006; 2 (1): 16-18.

  8. Cons MF. Marcadores bioquímicos de remodelado óseo. Rev Metabol Os Min 2003; 1 (3): 91–98.

  9. López MJM. Utilidad de los marcadores bioquímicos del recambio óseo en osteoporosis. Boletín de la Escuela de Medicina 1999; 28, No. 1-2.

  10. Álvarez L, Peris P. Marcadores del remodelado óseo. Manual práctico de osteoporosis y enfermedades del metabolismo mineral. Barcelona: Roche Diagnostics; 2002. [Versión electrónica]

  11. Reginster JY. Utilidad clínica de los marcadores bioquímicos de remodelación ósea. XIII Congreso Chileno de Osteología y Metabolismo Mineral (1); 2005. [Versión electrónica]

  12. Young MF. Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteopor Int 2003; 14 (suppl 3): S35-S42.

  13. Cortina GR, Calderón JS. Modelos de experimentación para el estudio del tejido óseo. REB 2004; 23 (3): 107-116.

  14. Menchén L, Ripoll C, Bretón C, Cuerda C, Camblor M, García-Peris P, González-Lara V, Cos E. Osteoporosis y enfermedad inflamatoria intestinal. Nutr Hosp 2005; 20 (1): 26-37.

  15. Bianchi ML. El problema de la osteoporosis en niños y adolescentes: diagnóstico y tratamiento. Rev Arg Osteol 2007; 6 (3): 18-26.

  16. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: An Overview. J Osteopor 2010; 55 (3): 97-127.

  17. Zárate A, Saucedo R, Basurto L. Recomendaciones para el manejo de la osteoporosis. Gac Med Mex 2004; 140 (2): 25-35.

  18. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs and Cbfa1. Endoc Rev 2000; 21: 393-411.

  19. Muñoz TM, Higuera LFM, Fernández GD. Avances en el conocimiento de la biología del osteoclasto: el sistema osteoprotegerina-ligando del RANK. Med Clin 2004; 122 (2): 75-77.

  20. Fernández-Tresguerres I et al. Bases fisiológicas de la regeneración ósea. Parte I: Histología y fisiología del tejido óseo. Med Oral Patol Oral Cir Bucal 2006; 11: E47-E51.

  21. Vega D, Maalouf N, Sakhaee K. The role of receptor activator of nuclear facctor-kB (RANK)/RANK ligand/ osteoprotegerin: Clinical Implications. J Clin Endocrinol Metab 2007; 97: 4514-4521.

  22. McLean R, Jacques P, Selhub J, Tucker K, Samelson E, Broe K, Hannan M, Cupples L, Kiel D. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-2049.

  23. Greenspan S, Resnick N, Parker R. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90: 2762-2767.

  24. Canalis E, Economides A, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endoc Rev 2003; 24: 218-235.

  25. Torres E, Mezquita P, de la Higuera M, Fernández D, Muñoz M. Actualización sobre la determinación de marcadores de remodelado óseo. Endocrinol Nutr 2003; 50 (6): 237-243.

  26. Paskalev M, Krastev S. Alterations in serum tartrate-resistant acid phosphatase and C-terminal telopeptide of type I collagen in experimental canine osteotomies fixed using 2 different techniques. Turk J Vet Anim Sci 2010; 34 (3): 1-17.

  27. Vega D, Maalouf N.M, Sakhaee K. The role of receptor activator of nuclear factor-kB (Rank)/Rank ligand/osteoprotegerin: Clinical implications. J Clin Endocrinol Metab 2007; 92: 4514-4521.

  28. Indumati V, Patil V. Biochemical markers of bone remodeling in osteoporosis current concepts. Journal of Clinical and Diagnostic Research 2010; 4: 2089-2097.

  29. Asociación Mexicana de Metabolismo Óseo y Mineral. Consenso Mexicano de Osteoporosis. Rev Metab Oseo Min 2003; 1 (1): 1-24.

  30. Mandalunis P. Remodelación ósea. Actualiz Osteol 2006; 2 (1): 16-18.

  31. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.

  32. Terrés AS, Tamayo y Orozco JA, Valle OS. Edad ósea: Estimación densitométrica y metabólica. Rev Mex Patol Clin 2002; 49 (1): 7-14.

  33. Bauer D, Sklarin P, Stone K, Black D, Nevitt M, Ensrud K, Arnaud C, Genant H, Garnero P, Delmas P, Lawaetz H, Cummings S. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bon Miner Res 1999; 14: 1404-1410.

  34. Wainwright S, Marshall L, Ensrud K, Cauley J, Black D, Hillier T, Hochberg M, Vogt M, Orwoll E. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90: 2787-2793.

  35. Nguyen N, Frost S, Center J, Eisman J, Nguyen T. Development of a nomogram for individualizing hip fracture risk in men and women. Osteopor Int 2007 18: 1109-1117.

  36. Vescini F. Diagnostic assessment of primary and HIV-induced osteoporosis. HAART and correlated pathologies 2008: 18-20.

  37. Willett A. Vitamin D status and its relationship with parathyroid hormone and bone mineral status in older adolescents. Proc Nutr Soc 2005; 64: 193-203.

  38. Turner L, Wallace L, Perry B, Bleeker J. Risk factors for Osteoporosis among middle-aged women. Am J Healt Behav 2004; 28 (3): 250-259.

  39. Ozdemir F, Rodoplu M. Benefit period using alendronate to increase bone mineral density in women with osteoporosis? Chin Med J 2005; 118 (5): 383-390.

  40. French L. Prevention and treatment of osteoporosis in postmenopausal women. JFP 2002: 875-882.

  41. Schurman L, Bagur A, Claus-Hermberg H, Messina DO, Negri A, Sánchez A. Guías para diagnóstico, prevención y tratamiento de la osteoporosis 2007. Rev Arg Osteol 2007; 6 (3): 27-42.

  42. Cauley J, Zmuda J, Wisniewski S, Krishnaswami S, Palermo L, Stone K, Black D, Nevitt M. Bone mineral density and prevalent vertebral fractures in men and women. Osteopor Int 2004; 15: 32-37.

  43. Looker A, Bauer D, Chesnut C, Gundberg C, Hochberg M, Klee G, Kleerekoper M, Watts N, Bell N. Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteopor Int 2000; 11: 467-480.

  44. Aguilera MB, Guerrero AM, Méndez TJ, Milián FS. Efecto del calcio dietético vs el citrato de calcio sobre marcadores bioquímicos convencionales en mujeres perimenopáusicas. Sal Publ Mex 2005; 47: 259-267.

  45. Eastell R, Wahner H, O`Fallon W, Amadio P, Ill J, Riggs L. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles and vertebral fracture syndrome. J Clin Invest 1989; 83: 168-174.

  46. Peel N, Moore D, Barrington N, Bax D, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995; 54: 801-806.

  47. Ionescu A, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur respir J 2003; 22: (46): 64s-75s.

  48. Tannirandorn P, Epstein S. Drug-Induced bone loss. Osteoporos Int 2000; 11: 637-659.

  49. Campusano C. Enfrentamiento clínico del paciente con osteoporosis. Bol Esc Med 1999; (28)1-2: 20-27.

  50. Zárate A, Hernández M, Morán C, Ángeles L. El enfoque moderno de la osteoporosis. Rev Fac Med UNAM 2003; 46 (2): 49-51.

  51. Schurman L et al. Guías para diagnóstico, prevención y tratamiento de la osteoporosis 2007. Rev Arg Osteol 2007; 6 (3): 27-42.

  52. Taskinen M, Saarinen-Pihkala U, Hovi L, Vettenranta K, Mäkitie O. Bone Health in Children and adolescents after Allogeneic Stem Cell transplantation. Cancer 2007; 110: 442-451.

  53. Schurman L et al. Abridged Argentine guidelines for the diagnosis, prevention, and treatment of osteoporosis 2007. Actualiz Osteol 2007; 3 (3): 117-136.

  54. Brown J, Fortier M. Canadian Consensus Conference on Osteoporosis, 2006 Update. JOGC 2006; 172: S95-S112.

  55. Eastell R, Boyle I, Compston J, Cooper C, Fogelman I, Francis R, Hosking D, Purdie D, Ralston S, Reeve J, Reid D, Russell R, Stevenson J. Management of male osteoporosis: Report of the UK Consensus Group. QJ Med 1998; 91: 71-92.

  56. Poole K, Compston J. Osteoporosis and its management. BMJ 2006; 333: 1251-1256.

  57. Alomran A. Osteoporosis-Related simultaneous four joints fractures and dislocation after a seizure: A case report. J Osteopor 2009; 25 (5): 35-47.

  58. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008; 134: 1244-1249.

  59. Basurto L, Saucedo R, Zárate A. Marcadores bioquímicos de remodelación ósea. Efectos del reemplazo hormonal en mujeres menopaúsicas. Rev Med IMSS 2002; 40 (3): 193-196.

  60. Guo C, Holland P, Jackson B, Hannon R, Rogers A, Harrison B, Eastell R. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 2000; 142: 451-459.

  61. Greenspan S, Resnick N, Parker R. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90: 2762-2767.

  62. Opara Usoro C, Uzoma Onyeukwu C, Chinyere Nsonwu A. Biochemiocal bone turnover markers in postmenopausal women in Calabar Municipality. Asian J. Biochem 2007; 2 (2): 130-135.

  63. Luporini GS, Lazaretti MC. Marcadores bioquímicos da remodelacao óssea na prática clínica. Arq Bras Endocrinol Metab 2002; 46 (1): 72-78.

  64. Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936.

  65. Lu Y, Genant H, Shepherd J, Zhao S, Mathur A, Fuerst T, Cummings S. Classification of osteoporosis based on bone mineral densities. J Bon Miner Res 2001; 16: 901-910.

  66. Schurman L et al. Guías para diagnóstico, prevención y tratamiento de la osteoporosis 2004. Rev Med Rosar 2005; 71: 68-77.

  67. Solomon D, Morris C, Cheng H, Cabral D, Katz J, Finkelstein J, Avorn J. Medication use patterns for osteoporosis: An assessment of guidelines, treatment rates and quality improvement interventions. Mayo Clin Proc 2005; 80 (2): 194-202.

  68. Bonnick S, Shulman L. Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am J Med 2006; 119 (4A): 25S-31S.

  69. Lenora J, Ivaska K, Gerdhem P. Use of bone turnover markers in osteoporosis. Clin Rev Bon Miner 2010, 8: 1-14.

  70. Prentice A, Goldberg G, Schoenmakers I. Vitamin D across the lifecycle: Physiology and biomarkers 1-3. Am J Clin Nutr 2008; 88 (suppl): 500S-506S.

  71. Anderson P, May B, Morris H. Vitamin D metabolism: New concepts and clinical implications. Fang Y, van Meurs J, Rivadeneira F, van Schoor N, van Leeuwen J, Lips P, Pols H, Uitterlinden A. Vitamin D receptor gene haplotype is associated with body height and bone size. J Clin Endocrinol Metab 2007; 92: 1491-1501.

  72. Fleet J, Hong J. Zhang Z. Reshaping the way we view vitamin D signaling and the role of vitamin D in health. Nutrition Research Reviews 2004; 17: 241-248.

  73. Zhang X, Zanello L. Vitamin D receptor-dependent 1a,25 (OH)2 vitamin D3-induced anti-apoptotic P13K/AKT signaling in osteoblasts. J Bon Miner Res 2008; 23: 1238-1248.

  74. Ángel MG, Ángel RM. Interpretación Clínica del Laboratorio. 5a ed. Editorial Panamericana; 1998.

  75. Villanueva VJ. Osteoporosis. Primera parte. Revista de Posgrado de la Cátedra VI de Medicina 2001; 110: 1-7.

  76. Metabolismo óseo y osteoporosis. Rev Menopausia 2008; 14 (3): 75-93.

  77. Skorija K, Cox M, Sisk J, Dowd D, MacDonald P, Thompson C, Demay M. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Molec Endocrinol 2005; 19: 855-862.

  78. Zanello L, Norman A. Rapid modulation of osteoblast ion channel responses by 1a,25 (OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. PNAS 2004; 101 (6): 1589-1594.

  79. Huhtakangas J, Olivera C, Bishop J, Zanello L, Norman A. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1a,25 (OH)2-vitamin D3 in vivo and in vitro. Molec Endocrinol 2004; 18: 2660-2671.

  80. Panda D, Miao D, Bolivar I, Li J, Huo R, Hendy G, Goltzman D. Inactivation of the 25-Hydroxyvitamin D 1 a-hidroxilase and vitamina D receptor demostrate independent and interdependent effects of calcium and vitamina D on skeletal and mineral homeostasis. J Biol Chemistry 2004; 279 (16): 16754-16766.

  81. Francis R, Anderson F, Patel S, Sahota O, Van Staa T. Calcium and vitamin D in the prevention of osteoporotic fractures. QJ Med 2006; 99: 355-363.

  82. Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003; 348: 287-294.

  83. Holick M. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.

  84. Guzmán R. Osteoporosis. Nutrición y tejido óseo. Calcio elemental. CES Medicina 2006; 20 (1): 65-75.

  85. Fatayerji D, Mawer E, Eastell R. The role of insulin-like growth factor I in age-related changes in calcium homeostasis in men. J Clin Endocrinol Metab 2000; 85: 4657-4662.

  86. Cañabete J, Zapata I, Oltra J, Hernández P. Marcadores bioquímicos de remodelado óseo en el estudio de la masa ósea en la mujer con menopausia reciente sin osteoporosis. Med Clin (Barc) 2005; 124 (7): 241-249.

  87. Vesper H, Demers L, Eastell R, Garnero P, Kleerekoper M, Robins S, Srivastava A, Warnic G, Watts N, Myers G. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chemistry 2002; 48 (2): 220-235.

  88. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87: 4431-4437.

  89. Méndez RE, Wyatt C. Excreción urinaria de deoxipiridinolina y su relación con la densidad mineral ósea, el estradiol sérico y los años de postmenopausia en mujeres mexicanas. Arch Latinoam Nutr 2004; 54 (4): 408-412.

  90. Di Stefano M, Formoso F, Tamone C, Aimo G, Mengozzi G, Bergui S, Isaia G. Short-term urine deoxypyridinoline biological variability in the first 5 years after menopause. Clin Chemistry 2005; 51 (11): 2189-2192.

  91. Blumsohn A, Naylor K, Assiri A, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chemistry 1995; 41 (11): 1592-1598.

  92. Muñoz Torres M, Reyes García R. Catepsina K y resorción ósea. REEMO 2006; 15 (4): 88-89.

  93. Al-Dehaimi A, Blumsohn A, Eastell R. Serum galactosyl hydroxylysine as a bichemical merker of bone resorption. Clin Chemistry 1999; 45 (5): 676-681.

  94. Van Meurs J, Dhonukshe-Rutten R, Pluijm S, van der Klift M, de Jonge R, Lindemans J, de Groot L, Hofman A, Witteman J, van Leeuwen J, Breteler M, Lips P, Pols H, Uitterlinden A. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-2041.

  95. Raisz L. Homocysteine and Osteoporotic fractures culprit or bystander? N Engl J Med 2004; 350: 2089-2090.

  96. Unnanuntana A, Gladnick B, Donnelly E, Lane J. Reseña sobre conceptos actuales. Evaluación del riesgo de fractura. J Bone Joint Surg 2010: 23 (3): 18-27.

  97. Foldes J, Parfitt A, Shih M, Rao D. Structural and geometric changes in iliac bone: Relationship to normal aging and osteoporosis. J Bon Miner Res 1991; 6 (7): 759-766.

  98. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteopor Int 2000; (suppl 6): S30-S44.

  99. Johnell O, Odén A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteopor Int 2002; 13: 523-526.

  100. 100.Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone 2006; 38: 694-700.

  101. Ivaska K, Lenora J, Gerdhem P, Akesson K, Väänänen H, Obrant K. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab 2008; 93 (7): 2622-2632.

  102. Ju H, Leung S, Brown B, Stringer M, Leigh S, Scherrer C, Shepard K, Jenkins D, Knudsen J, Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chemistry 1997; 43 (9): 1570-1576.

  103. Truchaud A, Le Neel T, Brochard H, Malvaux S, Moyon M, Cazaubiel M. New tools for laboratory design and management. Clin Chemistry 1997; 43 (9): 1709-1715.

  104. O´kane D, Ebert T, Hallaway B, Roberts S, Bhuiyan A, Tenner K. A laboratorian´s perspective on evaluation and implementation of new laboratory test. Clin Chemistry 1997; 43 (9): 1771-1780.

  105. Delmas P, Eastell R, Garnero P, Seibel M, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteopor Int 2000; (suppl 6): S2-S17.

  106. Kanis J, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeusw N, Pfleger B, Khaltaev N. Assessment of fracture risk. Osteopor Int 2005; 16: 581-589.

  107. Nguyen T, Pocock N, Eisman J. Interpretation of bone mineral density measurement and its change. J Clin Dens 2000; 3 (2): 107-119.

  108. Nogués XS, Sorli MR, Villar JG. Instrumentos de medida de adherencia al tratamiento. An Med Intern 2007, 24 (3): 138-141.

  109. Doménech M, Hernández A, Ricós C, Minchinela J, García-Lario J, Perich C, Álvarez V, Cava F, Biosca C, Simón M, Jiménez C. Variaciones biológicas en patologías: Revisión de datos y consecuencias clínicas. Rev Lab Clin 2008; 1 (1): 17-23.




2020     |     www.medigraphic.com